We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
23/10/2009 08:11 | cheers top..... just poached this from another bb and can I say that these are not my words but looks good to me as I see that it could get some press attention over the weekend... Ok guys been in here 9 months. The ticker is MEDG, you should have no problem buying it. I never have and have topped up a few times. Always been able to trade on line with Barclays. Perhaps the sudden interest is making it more difficult. Read the website, this company in my opinion is going to be massive. This will be the first of many partnership agreements. Readabout the guy with anemia who used to inject several times a day and now has not needed an injection for a year. These products are moving steadily towards commercialisation. The problem was always, whether they had the cash to keep going. It may take a couple of years but this could be massive. Today has been the most trades I've ever seen, on one occasion we went 6 weeks without a single trade. I know a lot of you will be day trading this, but for those who decide long term, be patient you could be substantially rewarded. please make up your own mind on this on the strength of the information provided on the rns ..... | 5pongebob | |
23/10/2009 08:08 | 5ponge...dont shout too loud or you will attract that nutter 8Trade. He will already be monitoring this one now as its on the top list, his favourite stalking ground.!!!! | topinfo | |
23/10/2009 08:06 | from...do we think they could be the partner...? Like the bits about they can link this to anaemia as well..........would have liked some more details about the partner though... | 5pongebob | |
23/10/2009 07:55 | trader......last pharma which announced some good news was pym and it went mental initially then settled.......to me as a lamen in this field and part time trader reacting to news and buying on the strength of it.......potentially this could be huge and dependant upon which partner is in with it will obviously depend upon where this will end up.....nice rise this morning though and would be nice if they released another rns stating who the pharma is they are in partnership with.........I would like to say it will get to the moon but I do hope someone with a bit more knowledge comes in to asssit us both... | 5pongebob | |
23/10/2009 07:52 | 5pongebob just googled market leader in haemophilia and came up with Baxter Healthcare Recognised As Market Leader In Haemophilia For The Fourth Year Running | fromthesidelines | |
23/10/2009 07:46 | wonder where this is going,, valued at what 10 million... any views? | tradermania | |
23/10/2009 07:43 | Question for anyone, can you tell me the difference between this and MEDU? able to buy MEDU through halifax but not MUDG. TIA | fromthesidelines | |
23/10/2009 07:38 | I also wonder who they could be in partnership with..........very tightly held and every buy pushes up the price....am I reading right a 7 mill order and an 8 mill mkt cap......mmmm | 5pongebob | |
23/10/2009 06:42 | I wonder who the major Pharma company is? Looks very good for a company with a £8.5 million Mark Cap AIMVHO RNS Number : 2665B Medgenics Inc 23 October 2009 ? Medgenics, Inc. ('Medgenics' or the 'Company') MEDGENICS SIGNS DEVELOPMENT AGREEMENT WITH MAJOR INTERNATIONAL PHARMA COMPANY Marks first step towards commercialization of Medgenics' Biopump tissue protein therapy technology Focus on sustained treatment of Hemophilia * Feasibility agreement worth up to $7 million (including preclinical development funding and an option to proceed to commercial agreement) * Medgenics' first Biopump agreement with a major healthcare corporation * Uses Biopump in a new application to produce blood clotting Factor VIII * Deal expected to enhance Medgenics' ongoing efforts towards commercial agreements for other applications of the Biopump platform technology Misgav, Israel; London, UK and Vienna, VA, - 23 October 2009 - Medgenics (AIM: MEDG and MEDU) is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia. This groundbreaking feasibility agreement is worth up to $7 million in payments that will include funding for preclinical development of Medgenics' Biopump protein technology to produce and deliver clotting protein Factor VIII for the sustained treatment of hemophilia. Under the terms of the agreement, Medgenics will receive $4 million to work exclusively with this partner for one year to develop a Biopump to test the feasibility of continuous production and delivery of this clotting protein. Additional payments totaling $3 million are payable upon Medgenics meeting certain technical milestones and upon the partner's exercise of an option to extend the exclusivity through an additional period to negotiate terms to commercialize the Biopump technology for Factor VIII. This is a new application of the Biopump tissue protein therapeutic platform, which has previously demonstrated success in the production of erythropoietin ("EPO") in treating renal anemia and interferon alpha for use in treating hepatitis-C. The market for Factor VIII is greater than $3.2 billion per year (La Marie 2008), and according to the World Federation of Hemophilia, some 400,000 people in the world have hemophilia. Dr. Andrew Pearlman, Chief Executive Officer of Medgenics, said: "We are very excited to have reached this key milestone toward commercialization of our technology. The fact that this agreement is for a new therapeutic application of our Biopump demonstrates the versatility of our platform technology. It further validates the belief that our platform can be applied to help treat many chronic diseases and will attract further interest from other major partners.The fact that a market leader in hemophilia has entered such an agreement at this early stage testifies to the promise of the Biopump technology for use in treating hemophilia. It reflects our mutual expectation that this feasibility program will be successful and will lead to a definitive agreement to complete the development and to commercialize this unique and exciting new therapeutic option which could make a major difference in the lives of hemophilic patients." "Medgenics' Biopump platform technology has already achieved unprecedented results in the sustained treatment of anemia; the only indication that we have tested in patients to date. In a Phase I/II clinical study using our EPODURE Biopumps to produce and deliver EPO in patients with chronic kidney disease, a single administration of EPODURE Biopumps has been shown to provide effective anemia treatment for up to 12 months without any need for additional EPO injections. We believe our Biopump technology will address many of the current challenges in healthcare and provide an important advance for the treatment of chronic disease." "While this first agreement is directed to the treatment of hemophilia, Medgenics is continuing its discussions with other potential partners with a view to signing additional agreements for other indications using different therapeutic proteins." | eggbird | |
08/10/2009 11:28 | AIM listed Medgenics has raised £0.265m through a placing of common shares at 6p each. The company, which has developed an alternative to the use of syringes in the medical world, told Sharecast back in August that it had been constrained by limited funds from performing more tests of its revolutionary technology. The funds will enable the company to stage tests of its Biopump technology as part of the process of gaining regulatory approval in the US, chief executive officer Dr. Andrew Pearlman told Sharecast. | andrbea | |
29/9/2009 13:02 | interview with CEO (Sept 14) video starts by itself | andrbea | |
29/9/2009 12:32 | Aug 27 2009 Medgenics has also recently moved significantly ahead in discussions with major pharmaceutical companies and with institutional investment funds. Advanced discussions are now underway towards potential partnership in the coming months to co-develop a Biopump producing Factor VIII protein for the treatment of hemophilia, a market greater than $3.5b/year (La Marie 2007). In addition, the Company has recently entered advanced discussions with institutional investors interested in multimillion dollar investment in Medgenics in the coming months. Medgenics is also in active due diligence with an Asian biopharma company that has conveyed its written interest in a combined investment in the Company and licensing agreement for collaboration in certain Biopump applications in selected Asian markets to be agreed. The Board is also pleased by recent serious interest by companies in other new applications of the Biopump platform, and believes that such interest demonstrates the attractiveness of the Biopump platform for strategic partners. The Directors believe that these discussions could lead to concrete steps in the coming months. | andrbea | |
03/9/2009 15:59 | NETECH, it will soar, in my view, in the next six months. Market cap around £8.5m. Have a look at the other thread though. It is more active: | sicilian_kan | |
03/9/2009 10:53 | This does Look Very Interseting this could soar ?! | netech | |
27/8/2009 09:25 | LOOKS VERY INTERESTING! TIDMMEDG RNS Number : 1018Y Medgenics Inc 27 August 2009 Medgenics, Inc. ('Medgenics' or the 'Company') PATIENT NEARING UNPRECEDENTED 11 MONTHS OF ANEMIA RELIEF IN CLINICAL TRIAL FROM SINGLE TREATMENT OF BIOPUMP TISSUE TECHNOLOGY NEWS FOLLOWS SIGNIFICANT INTEREST OF STRATEGIC PARTNER FOR NEW APPLICATION * EPODURE patient approaching 11 months continuous anemia relief from single treatment, and reaching one year anniversary without any injections of EPO; * Significant new interest from major pharmaceutical companies to develop a Biopump for new applications; * Serious new interest from institutional investors; and * Medgenics awarded $1.3 million Israeli government grant. August 27, 2009 - Medgenics (AIM:MEDG, MEDU) is pleased to announce that one of the patients, who was treated with the Company's EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company's phase I/II anemia trial in Israel. He has now gone a full year since his last EPO injection, while his hemoglobin level has been continuously maintained within the target range of 10-12 g/dl for this period. By contrast, conventional anemia treatment by EPO injections must be repeated up to 3 times every week to provide sustained treatment. To the best of the Directors' knowledge, nothing approaching EPODURE'S length of sustained anemia relief in patients has been shown from a single treatment of any other kind. The patient (#2), stated: "For me the treatment has been and continues to be successful, without complications or discomfort. At 72 years old, I continue to do physical work in the citrus groves several hours a day, but unlike in the previous year, I have not needed injections. The treatment has improved my quality of life." Medgenics' unique tissue-based EPODURE Biopump platform technology is proving to be effective in maintaining hemoglobin levels within the target range for many months in most of the patients treated so far, even at lowest dose of treatment, according to internationally renowned nephrologist, Dr. Anatole Besarab, who is a member of Medgenics' Scientific Advisory Board.The Company plans to present the study findings at the upcoming American Society of Nephrology meeting in October. Dr. Besarab has said: "With a patient now nearing 12 months without EPO injections and others for more than 6 months, it is becoming clearer that the EPODURE Biopump is able to produce sufficient erythropoietin to effectively elevate and then sustain hemoglobin levels in patients with sufficient administered dose.I am not aware of any other technology that can achieve such prolonged and sustained therapy from a single treatment. Additional studies are needed in a broader range of patients, and we look forward to them to further confirm these very positive results." Medgenics has also recently moved significantly ahead in discussions with major pharmaceutical companies and with institutional investment funds. Advanced discussions are now underway towards potential partnership in the coming months to co-develop a Biopump producing Factor VIII protein for the treatment of hemophilia, a market greater than $3.5b/year (La Marie 2007). In addition, the Company has recently entered advanced discussions with institutional investors interested in multimillion dollar investment in Medgenics in the coming months. Medgenics is also in active due diligence with an Asian biopharma company that has conveyed its written interest in a combined investment in the Company and licensing agreement for collaboration in certain Biopump applications in selected Asian markets to be agreed. The Board is also pleased by recent serious interest by companies in other new applications of the Biopump platform, and believes that such interest demonstrates the attractiveness of the Biopump platform for strategic partners. The Directors believe that these discussions could lead to concrete steps in the coming months. In addition to the closing and commitment of additional funds announced last week, which brought the total to $520,000, Medgenics notes that it was awarded a government grant in Q2/09 of $1.3 million from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. These funds will be received as government participation in approved R & D expenses incurred during the period April 2009 to March 2010. The OCS awards grants to industry in Israel to advance technological innovations. This is the fourth consecutive year that Medgenics has received this respected grant. Dr. Andrew Pearlman, CEO of Medgenics said "We are excited that we have a patient who is now reaching a full year of effective anemia treatment without any EPO injections and with only a single treatment of EPODURE. In this period a typical patient in the U.S. being treated per the FDA guidelines for EPO administration would receive up to 150 injections. Month by month we have drawn growing encouragement from the continuing positive results of the Biopump anemia study. We are pleased by the significant progress with potential partners and institutional investors which gives us great hope that this will yield concrete results in the coming months. Meanwhile, the Company continues its focused efforts to raise several million US$ in the coming months to enable it to continue and expand the clinical trial and our other operations and to realize the potential of the great opportunities it now has." The Company would also like to clarify that, further to the announcement made on 20 August 2009, included within the $55,000 debenture investment by "shareholders who are physicians with expertise in the clinical field addressed by Medgenics' lead product, EPODURE" was an investment of US $5,000 from Stephen McMurray, a director of the Company. For further information, contact: Medgenics, Inc.+972 4 902 8900 Dr. Andrew L. Pearlman | simonparker5 | |
07/5/2009 22:29 | Just seen this thread having set up another one today on MEDU. MEDG shares are restricted. MEDU are unrestricted. Better to pop over to my MEDU thread: | sicilian_kan |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions